Epidemiology of seropositive myasthenia gravis in Sardinia: A population-based study in the district of Sassari.
AChR-IgG
MuSK-IgG
incidence
prevalence
risk
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
08 Mar 2024
08 Mar 2024
Historique:
revised:
21
02
2024
received:
11
10
2023
accepted:
27
02
2024
medline:
8
3
2024
pubmed:
8
3
2024
entrez:
8
3
2024
Statut:
aheadofprint
Résumé
The global incidence and prevalence of myasthenia gravis (MG) range between 6-31/million and 10-37/100,000, respectively. Sardinia is a high-risk region for different immune-mediated disorders, but the epidemiology of MG remains unclear. We determined the epidemiology of MG with acetylcholine receptor (AChR)-immunoglobulin G (IgG) and muscle-specific tyrosine kinase (MuSK)-IgG in the district of Sassari (North-Western Sardinia; population, 325,288). From the laboratory of the University Hospital of Sassari (reference for AChR/MuSK-IgG testing in Sardinia since 1998) and the main neurology units in Sardinia, we retrospectively identified MG patients with (1) AChR-IgG and/or MuSK-IgG positivity by radioimmunoprecipitation assay; and (2) residency in the district of Sassari. Incidence (January 2010-December 2019) and prevalence (December 31, 2019) were calculated. A total of 202 patients were included (incident, 107; prevalent, 180). Antibody specificities were AChR (n = 187 [93%]) and MuSK (n = 15 [7%]). The crude MG incidence (95% confidence interval) was 32.6 (26.8-39.2)/million, while prevalence was 55.3 (47.7-63.9)/100,000. After age-standardization to the world population, incidence decreased to 18.4 (14.3-22.5)/million, while prevalence decreased to 31.6 (26.1-37.0)/100,000. Among incident cases, age strata (years) at MG onset were: <18 (2%), 18-49 (14%), 50-64 (21%), and ≥65 (63%). Sardinia is a high-risk region for MG, with a prevalence that exceeds the European threshold for rare disease. Identification of the environmental and genetic determinants of this risk may improve our understanding of disease pathophysiology.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : University of Sassari
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21:176-188.
Rodrigues E, Umeh E, Aishwarya NN, Cole A, Moy K. Incidence and prevalence of myasthenia gravis in the United States: a claims-based analysis. Muscle Nerve. 2023;69:166-171.
Songini M, Mannu C, Targhetta C, Bruno G. Type 1 diabetes in Sardinia: facts and hypotheses in the context of worldwide epidemiological data. Acta Diabetol. 2017;54:9-17.
Urru SA, Antonelli A, Sechi GM, Group MSW. Prevalence of multiple sclerosis in Sardinia: a systematic cross-sectional multi-source survey. Mult Scler. 2020;26:372-380.
Italian National Statistic Institute Web site; demographics. https://demo.istat.it
NIH Web site; World (WHO 2000-2025) Standard-Standard Populations-SEER Datasets. seer.cancer.gov/stdpopulations/world.who.html
Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021;14:7-16.
Santos E, Coutinho E, Moreira I, et al. Epidemiology of myasthenia gravis in Northern Portugal: frequency estimates and clinical epidemiological distribution of cases. Muscle Nerve. 2016;54:413-421.
Boldingh MI, Maniaol AH, Brunborg C, et al. Geographical distribution of myasthenia gravis in Northern Europe-results from a population-based study from two countries. Neuroepidemiology. 2015;44:221-231.
Aiello I, Pastorino M, Sotgiu S, et al. Epidemiology of myasthenia gravis in northwestern Sardinia. Neuroepidemiology. 1997;16:199-206.
Antonini G, Habetswallner F, Inghilleri M, et al. Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy. Heliyon. 2023;9:e16367.
Giagheddu M, Puggioni G, Sanna G, et al. Epidemiological study of myasthenia gravis in Sardinia, Italy (1958-1986). Acta Neurol Scand. 1989;79:326-333.
Montomoli C, Citterio A, Piccolo G, et al. Epidemiology and geographical variation of myasthenia gravis in the province of Pavia, Italy. Neuroepidemiology. 2012;38:100-105.
Sardu C, Cocco E, Mereu A, et al. Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. PLoS One. 2012;7:e32487.
Westerberg E, Punga AR. Epidemiology of myasthenia gravis in Sweden 2006-2016. Brain Behav. 2020;10:e01819.
Niks EH, Kuks JB, Verschuuren JJ. Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands. J Neurol Neurosurg Psychiatry. 2007;78:417-418.
Tsiamalos P, Kordas G, Kokla A, Poulas K, Tzartos SJ. Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece. Eur J Neurol. 2009;16:925-930.
Delitala AP, Pilia MG, Ferreli L, et al. Prevalence of unknown thyroid disorders in a Sardinian cohort. Eur J Endocrinol. 2014;171:143-149.
Cortes-Vicente E, Alvarez-Velasco R, Segovia S, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020;94:e1171-e1180.
Monte G, Spagni G, Damato V, Iorio R, Marino M, Evoli A. Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? J Neurol. 2021;268:1803-1807.
Somnier FE. Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology. 2005;65:928-930.
Marcus JH, Posth C, Ringbauer H, et al. Genetic history from the middle Neolithic to present on the Mediterranean Island of Sardinia. Nat Commun. 2020;11:939.
Maddison P, Sadalage G, Ambrose PA, Jacob S, Vincent A. False-positive acetylcholine receptor antibody results in patients without myasthenia gravis. J Neuroimmunol. 2019;332:69-72.
Evoli A, Spagni G, Monte G, Damato V. Heterogeneity in myasthenia gravis: considerations for disease management. Expert Rev Clin Immunol. 2021;17:761-771.
Damato V, Spagni G, Monte G, et al. Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry. 2022;93:995-1000.
Mirian A, Nicolle MW, Edmond P, Budhram A. Comparison of fixed cell-based assay to radioimmunoprecipitation assay for acetylcholine receptor antibody detection in myasthenia gravis. J Neurol Sci. 2022;432:120084.